The Voigt Group and PHOENIX Pharma Switzerland intend to bring their subsidiaries Voigt AG and Voigt Industrie Service AG, respectively Amedis-UE AG, into a 50/50 joint venture.
Joint venture planned for Voigt Holding AG and PHOENIX Pharma Switzerland
The challenges of the Swiss healthcare market will continue to grow in the future, which will increase the overall pressure on market participants. An optimal combination of product and service ranges as well as comprehensive market coverage are therefore crucial for a competitive and innovative player in the healthcare supply chain.
The Voigt Group and PHOENIX Pharma Switzerland have therefore decided to bring their subsidiaries Voigt AG and Voigt Industrie Service AG and Amedis-UE AG respectively into a 50/50 joint venture. The two well-established and financially sound companies have a similar understanding of business as well as ideally complementary offerings and competencies in the supply chain. They are therefore a very good fit and together they will meet the requirements of the future. Pharmacies BENU SA and Pharmapost AG are not part of the joint venture, which focuses on logistics services. They will be developed independently by PHOENIX Pharma Switzerland.
Subject to approval by the Swiss Competition Commission (WEKO), this joint venture would create a new, competent and sustainable player covering the entire supply chain of the Swiss healthcare market. In the future, the joint venture would provide its high-quality, efficient and innovative services for manufacturers, independent service providers and the specialised trade even more competitively, taking special account of the peculiarities of the Swiss healthcare market. or example, warehouse and delivery logistics could be optimised and made more flexible, the product range could be expanded and new digital platforms could be developed, that allow simplified and more direct access to services, product ranges and information.
Until the approval of the transaction by the Competition Commission and until its execution, the Voigt Group and PHOENIX Pharma Switzerland will continue to have a competitive relationship. Thus, for employees, customers, partner companies and suppliers of both companies, everything will remain as usual in the meantime.
The antitrust investigations by the Competition Commission will begin in the next few days. After signing the contracts, the Voigt Group and PHOENIX Pharma Switzerland will start planning the implementation of the joint venture in compliance with the relevant antitrust requirements. As soon as the approval of the Competition Commission and an implementation plan are available, the two companies will be in a position to communicate its contents. We expect this to be the case in six to eight months.
Until the approval of the transaction by the Competition Commission and until its execution, the Voigt Group and PHOENIX Pharma Switzerland will continue to have a competitive relationship. Thus, for employees, customers, partner companies and suppliers of both companies, everything will remain as usual in the meantime.